PBAC's latest decision on Cobicistat + elvitegravir + emtricitabine + tenofovir: Recommended with restriction (2013). Considered for Treatment of HIV infection in treatment-naïve and treatment-experienced patients with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2013
Submissions
1
2013 → 2013
Eligible population
Treatment-naïve and treatment-experienced adults with HIV infection and a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease.
Therapy area
Infectious disease
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
ORR
Pivotal trial size
700 patients
Key trials
GS-0101, GS-0102, GS-0103
Comparator
Atripla (tenofovir/emtricitabine/efavirenz)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. PBAC recommended listing on a cost-minimisation basis with Atripla.